Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and ...

Groundbreaking research unveils potential link between cytomegalovirus and Alzheimer's disease, offering new hope for ...

Research reveals how herpes simplex virus-1 may contribute to Alzheimer’s disease, offering new insights into the disease’s ...

More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

There is a potential link between Alzheimer's disease and the herpes simplex virus-1 (HSV-1), which is a common cause for ...

A new surgical treatment for Alzheimer’s disease is showing promise in a clinical trial under way in Chinese hospitals. One ...

Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...